EGFR and neoplasm: In another phase I/II trial, a combination of everolimus and gefitinib [epidermal growth factor receptor (EGFR) inhibitors] caused a rapid increase in PSA level, though the standardized uptake value was transient, thus it was not able to affect tumor growth significantly.